Chronic Hepatitis News

Direct-acting antivirals present not only a highly successful therapy for treatment-naive patients with hepatitis C but also a curative option for patients who could not undergo treatment with interferon-based regimens or failed prior treatment courses.

Patients with chronic liver disease had increasing rates of hospitalization, longer hospital stay, more readmissions and less access to post-acute care compared with patients with other chronic diseases, according to a recently published study.

Outcome Health announced a partnership with the American Liver Foundation to launch a nationwide campaign to promote the recently updated hepatitis C screening recommendations and raise awareness of liver disease, according to a press release.

Baseline resistance associated substitutions did not impact sustained virologic response among direct-acting antiviral-experienced patients who underwent hepatitis C therapy with Vosevi for 12 weeks, according to a recently published study.

The FDA recently approved a thrombocytopenia therapy for adults with chronic liver disease and a combination therapy for advanced metastatic hepatocellular carcinoma. Along with these advancements, multiple societies have recently provided grants or investments into liver disease research.

The World Health Organization has added ravidasvir as a future pangenotypic direct-acting antiviral to the list of recommended therapies in their Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C, according to a press release.

The FDA recently approved safety and efficacy revisions to the Mavyret label based on data from a hepatitis C/HIV-1 collection study and a liver and renal transplant study.

Overall survival rates were not significantly different between patients with alcoholic hepatitis who received standard care and those who received extracorporeal cellular therapy with standard care, according to recently published data. However, younger patients with lower MELD may benefit from the treatment.

Eiger BioPharmaceuticals announced the first patient enrollment in its phase 2 study of combination interferon lambda with ritonavir-boosted lonafarnib, according to a press release.

Patients who were negative for hepatitis C virus and received HCV-infected kidneys and antiviral treatment were clear of the disease and experienced good renal function up to a year after transplantation, according to study results recently published in the Annals of Internal Medicine.